Last Updated: September 28, 2026

Details for New Drug Application (NDA): 206333

✉ Email this page to a colleague

NDA 206333 describes KYBELLA, which is a drug marketed by Abbvie and is included in one NDA. It is available from one supplier. There are fourteen patents protecting this drug and one Paragraph IV challenge. Additional details are available on the KYBELLA profile page.

The generic ingredient in KYBELLA is deoxycholic acid. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the deoxycholic acid profile page.

Summary for 206333

Tradename:	KYBELLA
Applicant:	Abbvie
Ingredient:	deoxycholic acid
Patents:	14

Pharmacology for NDA: 206333

Physiological Effect	Decreased Cell Membrane Integrity

Medical Subject Heading (MeSH) Categories for 206333

Cholagogues and Choleretics

Suppliers and Packaging for NDA: 206333

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
KYBELLA	deoxycholic acid	SOLUTION;SUBCUTANEOUS	206333	NDA	Kythera Biopharmaceuticals Inc.	61168-101	61168-101-03	2 VIAL, GLASS in 1 CARTON (61168-101-03) / 2 mL in 1 VIAL, GLASS
KYBELLA	deoxycholic acid	SOLUTION;SUBCUTANEOUS	206333	NDA	Kythera Biopharmaceuticals Inc.	61168-101	61168-101-04	4 VIAL, GLASS in 1 CARTON (61168-101-04) / 2 mL in 1 VIAL, GLASS (61168-101-01)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION;SUBCUTANEOUS			Strength	20MG/2ML (10MG/ML)
Approval Date:	Apr 29, 2015	TE:	AP	RLD:	Yes
Patent:	10,500,214	Patent Expiration:	Mar 2, 2030	Product Flag?	Y	Substance Flag?		Delist Request?
Patent:	12,161,653	Patent Expiration:	Feb 17, 2032	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	IMPROVEMENT IN THE APPEARANCE OF MODERATE TO SEVERE CONVEXITY OR FULLNESS ASSOCIATED WITH SUBMENTAL FAT IN ADULTS BY MEANS OF REDUCING SUBMENTAL FAT VOLUME AS DESCRIBED IN THE APPROVED LABELING
Patent:	7,622,130	Patent Expiration:	Dec 10, 2027	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	METHOD FOR REDUCTION OF SUBMENTAL FAT

Expired US Patents for NDA 206333

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	KYBELLA	deoxycholic acid	SOLUTION;SUBCUTANEOUS	206333-001	Apr 29, 2015	8,298,556	⤷ Start Trial
Abbvie	KYBELLA	deoxycholic acid	SOLUTION;SUBCUTANEOUS	206333-001	Apr 29, 2015	8,846,066	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.